Charles S. Fuchs

Erasca, Inc, a clinical-stage precision oncology company focused on developing therapies for cancers driven by the RAS/MAPK pathway, has appointed Charles S. Fuchs, M.D., M.P.H., as President of Research and Development (R&D).

Dr. Fuchs brings more than three decades of experience in oncology, spanning cancer research, clinical care, scientific innovation and biopharmaceutical drug development.
Most recently, Dr. Fuchs served as Chief Medical Officer of Tubulis, which was acquired by Gilead, where he oversaw clinical strategy and pipeline development. Previously, he served as Senior Vice President and Global Head of Oncology and Hematology Product Development at Genentech and Roche. In that role, he led the development of multiple therapies through regulatory approval, including Lunsumio®, Columvi™, Polivy® and Tecentriq®.

Before entering the biopharmaceutical industry, Dr. Fuchs served as Director of the Yale Cancer Center and Physician-in-Chief at Smilow Cancer Hospital. During his tenure, he contributed to the launch of several biotechnology companies and founded EvolveImmune Therapeutics.

Earlier in his career, Dr. Fuchs was a professor of medicine at Harvard Medical School and served as Chief of the Gastrointestinal Oncology Division and Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. He established leading research programs focused on gastrointestinal cancers and cancer epidemiology.

Dr. Fuchs also serves on the Board of Directors of CytomX Therapeutics and as a Senior Advisor to Frazier Life Sciences. He is board-certified in medical oncology and earned his M.D. from Harvard Medical School and M.P.H. from Harvard T.H. Chan School of Public Health.

His appointment strengthens Erasca’s R&D leadership as the company advances its precision oncology pipeline targeting RAS/MAPK pathway-driven cancers.